NCT00834067View on ClinicalTrials.gov

Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

November 30, 2003

Study Completion Date

November 30, 2003

Conditions
Healthy
Interventions
DRUG

Moexipril HCl/hydrochlorothiazide 15/25 mg tablets

1 x 15/25 mg

DRUG

UNIRETIC® 15/25 mg tablets

1 x 15/25 mg

Trial Locations (2)

63301

Gateway Medical Research, Inc., Saint Charles

77099

Bioassay Laboratory, Inc., Houston

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00834067 - Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions | Biotech Hunter | Biotech Hunter